NP
PMCB icon

NorthRock Partners’s PharmaCyte Biotech PMCB Stock Holding History

NorthRock Partners’s Portfolio PMCB Stock Details PMCB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-37,164
Closed -$118K – 353
2021
Q3 		$118K Buy
+37,164
New +$131K 0.01% 274

Other funds holding PMCB

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EPM
Equitec Proprietary Markets Chicago, Illinois $559M AUM 230.29% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
AC
Ayrton Capital Westport, Connecticut $14.7M AUM 12.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SFI
Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return

NorthRock Partners's PMCB Position: Q4 2021 in Review

NorthRock Partners sold out of PharmaCyte Biotech (PMCB) in Q4 2021, closing a stake of 37,164 shares — an estimated $118K sold.

NorthRock Partners first reported a position in PMCB in Q3 2021 and held it in 1 quarter. The position peaked at $118K in Q3 2021. 26 funds tracked by Wall St. Rank hold PMCB as of Q4 2021.

  • NorthRock Partners reported no remaining PharmaCyte Biotech position as of Q4 2021 after selling out during the quarter.
  • NorthRock Partners sold 37,164 PharmaCyte Biotech shares in Q4 2021, an estimated $118K.
  • NorthRock Partners first reported a position in PharmaCyte Biotech in Q3 2021 and held it in 1 quarter.
  • NorthRock Partners's PharmaCyte Biotech position peaked at $118K in Q3 2021.
  • 26 funds tracked by Wall St. Rank held PharmaCyte Biotech as of Q4 2021.

Based on NorthRock Partners's 13F filing for Q4 2021, filed 7 Feb 2022.